These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10338102)

  • 21. [Mechanism of action of piracetam on cerebral circulation].
    Akopian VP; Balian LS
    Farmakol Toksikol; 1987; 50(1):38-41. PubMed ID: 3556550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
    Studzinski CM; Araujo JA; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease.
    Eckert GP; Cairns NJ; Müller WE
    J Neural Transm (Vienna); 1999; 106(7-8):757-61. PubMed ID: 10907734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piracetam: physiological disposition and mechanism of action.
    Tacconi MT; Wurtman RJ
    Adv Neurol; 1986; 43():675-85. PubMed ID: 3946121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nootropes (cognition enhancers) and neuroprotectors].
    Vornin TA; Seredenin SB
    Eksp Klin Farmakol; 2007; 70(4):44-58. PubMed ID: 18078043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Participation of GABA--benzodiazepine receptor complex in the anxiolytic effect of piracetam].
    Moldavkin GM; Voronina TA; Neznamov GG; Maletova OK; Eliava NV
    Eksp Klin Farmakol; 2006; 69(3):7-9. PubMed ID: 16878489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nootropic effect of BR-16A (Mentat), a psychotropic herbal formulation, on cognitive deficits induced by prenatal undernutrition, postnatal environmental impoverishment and hypoxia in rats.
    Bhattacharya SK
    Indian J Exp Biol; 1994 Jan; 32(1):31-6. PubMed ID: 8045602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy of cognitive disorders in geriatric subjects.
    Goodnick P; Gershon S
    J Clin Psychiatry; 1984 May; 45(5):196-209. PubMed ID: 6327657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension and cognitive function in the elderly.
    Cherubini A; Lowenthal DT; Paran E; Mecocci P; Williams LS; Senin U
    Am J Ther; 2007; 14(6):533-54. PubMed ID: 18090879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of the cerebrovascular effect of piracetam].
    Mirzoian RS; Gan'shina TS
    Biull Eksp Biol Med; 1985 Jan; 99(1):64-6. PubMed ID: 3967075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of the nootropic agents piracetam and GBS-111 on potential-dependent ion channels in the neuronal membrane].
    Solntseva EI; Bukanova IuV; Ostrovskaia RU; Gudasheva TA; Voronina TA; Skrebitskiĭ VG
    Biull Eksp Biol Med; 1996 Feb; 121(2):151-5. PubMed ID: 9026117
    [No Abstract]   [Full Text] [Related]  

  • 32. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
    Karasawa J; Hashimoto K; Chaki S
    Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Individual sensitivity of Wistar rats to piracetam].
    Nikol'skaia KA; Kondrashevskaia MV; Eremina LV
    Ross Fiziol Zh Im I M Sechenova; 2007 Nov; 93(11):1308-18. PubMed ID: 18198598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.
    Vernon MW; Sorkin EM
    Drugs Aging; 1991 Jan; 1(1):17-35. PubMed ID: 1794001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piracetam: a review of pharmacological properties and clinical uses.
    Winblad B
    CNS Drug Rev; 2005; 11(2):169-82. PubMed ID: 16007238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis.
    Peuvot J; Schanck A; Deleers M; Brasseur R
    Biochem Pharmacol; 1995 Oct; 50(8):1129-34. PubMed ID: 7488225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of WEB 1881-FU, a central cholinergic agent, which enhances cognition and cerebral metabolism.
    Kuhn FJ; Schingnitz G; Lehr E; Montagna E; Hinzen HD; Giachetti A
    Arch Int Pharmacodyn Ther; 1988; 292():13-34. PubMed ID: 3395164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.
    Leuner K; Kurz C; Guidetti G; Orgogozo JM; Müller WE
    Front Neurosci; 2010; 4():. PubMed ID: 20877425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Piracetam inhibits Pavlovian extinction and reversal learning in a spatial task for rats.
    Christoffersen GR; Kemp A; Orlygsdottir G
    Neuropharmacology; 1998 Jun; 37(6):815-25. PubMed ID: 9707295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.